Auto-antibodies to I2-F1-ATPase and vimentin in malignant mesothelioma.

Auto-antibodies to I2-F1-ATPase and vimentin in malignant mesothelioma.

Patients with Malignant Mesothelioma develop unidentified auto-antibodies to MM tumour antigens. This study was conducted to identify the targets of MM patient auto-antibodies in order to try to understand more of the anti-tumour response and to determine if these antibodies might be helpful for diagnosis or prognostication.